iShares Genomics Immunology and Healthcare ETF (IDNA)
Market Closed
16 Oct, 08:00 PM
$
40. 54
-1.51
-3.591%
$
197.17M Market Cap
0.45% Div Yield
204,108 Volume
$ 42.05
Previous Close 
Want to track IDNA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
IDNA: 3 Catalysts To Watch Closely
IDNA jumped 13.53% in one day on 2.8x average volume after three catalysts, including Moderna's and Merck's positive Phase 3 INTerpath-001 data. IDNA trades at a 14.90x forward P/E, implying a 6.7% theoretical earnings yield. Closing the valuation gap with XBI's forward multiple would mechanically add about 29.5% to IDNA's price as a one-time re-rating.
Seekingalpha | 1 month ago
IDNA: The Cutting Edge Of Medical Science Is A Risky Investment
The iShares Genomics Immunology and Healthcare ETF is invested in 49 companies involved in genomics, immunology and bioengineering. Compared with the biotechnology benchmark IBB, IDNA has value characteristics, but has greatly underperformed, losing over 20% since its inception. Among genomics-focused ETFs, PBE offers a relatively safer choice with better performance and lower volatility.
Seekingalpha | 1 year ago
2026 © Marketlog. All Rights Reserved.
